{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T14:52:19Z","timestamp":1794840739519,"version":"4.9.1"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T00:00:00Z","timestamp":1740096000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T00:00:00Z","timestamp":1740096000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100013041","name":"Bloomberg~Kimmel Institute for Cancer Immunotherapy, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013041","id-type":"DOI","asserted-by":"publisher"}]},{"name":"The Marilyn and Michael Glosserman Fund for Basal Cell Carcinoma and Melanoma Research"},{"name":"The Barney Family Foundation"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Precis. Onc."],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Enhancer of zeste homolog 2 (EZH2) is an essential epigenetic regulator of H3K27 histone methylation and is mutated or overexpressed in a wide variety of cancers. In melanoma, EZH2 overexpression contributes to excessive trimethylation of H3K27 on tumor suppressor genes and has been proposed to be a mechanism of tumor progression and metastasis. EZH2-targeted therapies have been successfully used to treat patients with follicular lymphoma and epithelioid sarcoma, but their clinical use in melanoma has not been described. Here, we describe a pediatric patient with multiply relapsed melanoma harboring an <jats:italic>EZH2<\/jats:italic> A692V missense mutation, treated adjuvantly with the EZH2 inhibitor tazemetostat, who experienced a prolonged relapse-free survival.<\/jats:p>","DOI":"10.1038\/s41698-025-00826-8","type":"journal-article","created":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T04:55:10Z","timestamp":1740113710000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Relapse-free survival in a pediatric patient with recurrent EZH2-mutant melanoma treated with adjuvant tazemetostat"],"prefix":"10.1038","volume":"9","author":[{"given":"Erin E.","family":"Resch","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stavriani C.","family":"Makri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Ghanem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ezra G.","family":"Baraban","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth J.","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan R.","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evan J.","family":"Lipson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7116-0605","authenticated-orcid":false,"given":"Christine A.","family":"Pratilas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,21]]},"reference":[{"key":"826_CR1","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.1080\/10428194.2018.1430795","volume":"59","author":"N Gulati","year":"2018","unstructured":"Gulati, N., B\u201aguelin, W. & Giulino-Roth, L. Enhancer of zeste homolog 2 (EZH2) inhibitors. Leuk. Lymphoma 59, 1574\u20131585 (2018).","journal-title":"Leuk. Lymphoma"},{"key":"826_CR2","doi-asserted-by":"publisher","first-page":"5449","DOI":"10.1158\/0008-5472.CAN-20-2147","volume":"80","author":"ML Eich","year":"2020","unstructured":"Eich, M. L., Athar, M., Ferguson, J. E. 3rd, & Varambally, S. EZH2-targeted therapies in cancer: Hype or a Reality. Cancer Res. 80, 5449\u20135458 (2020).","journal-title":"Cancer Res."},{"key":"826_CR3","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1016\/S1470-2045(20)30451-4","volume":"21","author":"M Gounder","year":"2020","unstructured":"Gounder, M. et al. Tazemetostat in advanced epithelioid sarcoma with loss of INI1\/SMARCB1: an international, open-label, phase 2 basket study. Lancet Oncol. 21, 1423\u20131432 (2020).","journal-title":"Lancet Oncol."},{"key":"826_CR4","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1016\/S1470-2045(20)30441-1","volume":"21","author":"F Morschhauser","year":"2020","unstructured":"Morschhauser, F. et al. Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial. Lancet Oncol. 21, 1433\u20131442 (2020).","journal-title":"Lancet Oncol."},{"key":"826_CR5","doi-asserted-by":"publisher","first-page":"1610","DOI":"10.1158\/1541-7786.MCR-10-0398","volume":"8","author":"H Li","year":"2010","unstructured":"Li, H., Cai, Q., Godwin, A. K. & Zhang, R. Enhancer of zeste homolog 2 promotes the proliferation and invasion of epithelial ovarian cancer cells. Mol. Cancer Res. 8, 1610\u20131618 (2010).","journal-title":"Mol. Cancer Res."},{"key":"826_CR6","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-10-524","volume":"10","author":"N Wagener","year":"2010","unstructured":"Wagener, N. et al. Enhancer of zeste homolog 2 (EZH2) expression is an independent prognostic factor in renal cell carcinoma. BMC Cancer 10, 524 (2010).","journal-title":"BMC Cancer"},{"key":"826_CR7","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1200\/JCO.2005.01.5180","volume":"24","author":"IM Bachmann","year":"2006","unstructured":"Bachmann, I. M. et al. EZH2 expression is associated with high proliferation rate and aggressive tumor subgroups in cutaneous melanoma and cancers of the endometrium, prostate, and breast. J. Clin. Oncol. 24, 268\u2013273 (2006).","journal-title":"J. Clin. Oncol."},{"key":"826_CR8","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1080\/15384047.2016.1167291","volume":"17","author":"F Mahmoud","year":"2016","unstructured":"Mahmoud, F. et al. Role of EZH2 histone methyltrasferase in melanoma progression and metastasis. Cancer Biol. Ther. 17, 579\u2013591 (2016).","journal-title":"Cancer Biol. Ther."},{"key":"826_CR9","doi-asserted-by":"publisher","first-page":"2442","DOI":"10.1016\/j.jid.2020.02.042","volume":"140","author":"J Tiffen","year":"2020","unstructured":"Tiffen, J. et al. EZH2 cooperates with DNA methylation to downregulate key tumor suppressors and IFN gene signatures in melanoma. J. Invest. Dermatol. 140, 2442\u20132454.e2445 (2020).","journal-title":"J. Invest. Dermatol."},{"key":"826_CR10","doi-asserted-by":"publisher","DOI":"10.1186\/s13148-020-0818-7","volume":"12","author":"F Hoffmann","year":"2020","unstructured":"Hoffmann, F. et al. H3K27me3 and EZH2 expression in melanoma: relevance for melanoma progression and response to immune checkpoint blockade. Clin. Epigenetics 12, 24 (2020).","journal-title":"Clin. Epigenetics"},{"key":"826_CR11","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-46422-5","volume":"15","author":"C Li","year":"2024","unstructured":"Li, C. et al. Mi-2beta promotes immune evasion in melanoma by activating EZH2 methylation. Nat. Commun. 15, 2163 (2024).","journal-title":"Nat. Commun."},{"key":"826_CR12","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1093\/jnci\/djad085","volume":"115","author":"SN Chi","year":"2023","unstructured":"Chi, S. N. et al. Tazemetostat for tumors harboring SMARCB1\/SMARCA4 or EZH2 alterations: results from NCI-COG pediatric MATCH APEC1621C. J. Natl. Cancer Inst. 115, 1355\u20131363 (2023).","journal-title":"J. Natl. Cancer Inst."},{"key":"826_CR13","doi-asserted-by":"publisher","first-page":"290","DOI":"10.6004\/jnccn.2024.0036","volume":"22","author":"SM Swetter","year":"2024","unstructured":"Swetter, S. M. et al. NCCN Guidelines(R) insights: melanoma: cutaneous, Version 2.2024. J. Natl. Compr. Canc. Netw. 22, 290\u2013298, https:\/\/doi.org\/10.6004\/jnccn.2024.0036 (2024).","journal-title":"J. Natl. Compr. Canc. Netw."},{"key":"826_CR14","doi-asserted-by":"publisher","unstructured":"Dalton, W.B. et al. Personalized medicine in the oncology clinic: implementation and outcomes of the johns hopkins molecular tumor board. JCO Precis. Oncol. https:\/\/doi.org\/10.1200\/PO.16.00046 (2017).","DOI":"10.1200\/PO.16.00046"},{"key":"826_CR15","doi-asserted-by":"publisher","unstructured":"Chi, S.N. et al. Phase I study of tazemetostat, an enhancer of zeste homolog-2 inhibitor, in pediatric pts with relapsed\/refractory integrase interactor 1-negative tumors. J. Clin. Oncol. https:\/\/doi.org\/10.1200\/JCO.2020.38.15 (2020).","DOI":"10.1200\/JCO.2020.38.15"},{"key":"826_CR16","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1038\/nature09784","volume":"469","author":"R Margueron","year":"2011","unstructured":"Margueron, R. & Reinberg, D. The Polycomb complex PRC2 and its mark in life. Nature 469, 343\u2013349 (2011).","journal-title":"Nature"},{"key":"826_CR17","doi-asserted-by":"publisher","first-page":"2127","DOI":"10.2217\/fon-2020-1244","volume":"17","author":"E Julia","year":"2021","unstructured":"Julia, E. & Salles, G. EZH2 inhibition by tazemetostat: mechanisms of action, safety and efficacy in relapsed\/refractory follicular lymphoma. Future Oncol. 17, 2127\u20132140 (2021).","journal-title":"Future Oncol."},{"key":"826_CR18","doi-asserted-by":"publisher","first-page":"3165","DOI":"10.1182\/blood-2013-04-496893","volume":"122","author":"C B\u00f6d\u00f6r","year":"2013","unstructured":"B\u00f6d\u00f6r, C. et al. EZH2 mutations are frequent and represent an early event in follicular lymphoma. Blood 122, 3165\u20133168 (2013).","journal-title":"Blood"},{"key":"826_CR19","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2017.32","volume":"7","author":"S Huet","year":"2017","unstructured":"Huet, S. et al. EZH2 alterations in follicular lymphoma: biological and clinical correlations. Blood Cancer J. 7, e555 (2017).","journal-title":"Blood Cancer J."},{"key":"826_CR20","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.1182\/blood.2019003535","volume":"135","author":"SE Lacy","year":"2020","unstructured":"Lacy, S. E. et al. Targeted sequencing in DLBCL, molecular subtypes, and outcomes: a Haematological Malignancy Research Network report. Blood 135, 1759\u20131771 (2020).","journal-title":"Blood"},{"key":"826_CR21","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.3390\/cancers15051569","volume":"15","author":"D Bekric","year":"2023","unstructured":"Bekric, D. et al. Evaluation of Tazemetostat as a Therapeutically Relevant Substance in Biliary Tract Cancer. Cancers 15, 1569 (2023).","journal-title":"Cancers"},{"key":"826_CR22","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-023-02025-6","volume":"40","author":"Y Liu","year":"2023","unstructured":"Liu, Y. & Yang, Q. The roles of EZH2 in cancer and its inhibitors. Med. Oncol. 40, 167 (2023).","journal-title":"Med. Oncol."},{"key":"826_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2024.104972","volume":"100","author":"Y Guo","year":"2024","unstructured":"Guo, Y. et al. Regulation of EZH2 protein stability: new mechanisms, roles in tumorigenesis, and roads to the clinic. EBioMedicine 100, 104972 (2024).","journal-title":"EBioMedicine"},{"key":"826_CR24","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-30105-0","volume":"13","author":"L Zhang","year":"2022","unstructured":"Zhang, L. et al. EZH2 engages TGFbeta signaling to promote breast cancer bone metastasis via integrin beta1-FAK activation. Nat. Commun. 13, 2543 (2022).","journal-title":"Nat. Commun."},{"key":"826_CR25","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.neo.2016.01.003","volume":"18","author":"J Tiffen","year":"2016","unstructured":"Tiffen, J., Wilson, S., Gallagher, S. J., Hersey, P. & Filipp, F. V. Somatic copy number amplification and hyperactivating somatic mutations of EZH2 correlate with DNA methylation and drive epigenetic silencing of genes involved in tumor suppression and immune responses in melanoma. Neoplasia 18, 121\u2013132 (2016).","journal-title":"Neoplasia"},{"key":"826_CR26","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms7051","volume":"6","author":"D Zingg","year":"2015","unstructured":"Zingg, D. et al. The epigenetic modifier EZH2 controls melanoma growth and metastasis through silencing of distinct tumour suppressors. Nat. Commun. 6, 6051 (2015).","journal-title":"Nat. Commun."},{"key":"826_CR27","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-53636-x","volume":"9","author":"I Ticha","year":"2019","unstructured":"Ticha, I. et al. A comprehensive evaluation of pathogenic mutations in primary cutaneous melanomas, including the identification of novel loss-of-function variants. Sci. Rep. 9, 17050 (2019).","journal-title":"Sci. Rep."},{"key":"826_CR28","doi-asserted-by":"publisher","first-page":"1918","DOI":"10.1158\/1535-7163.MCT-13-0804","volume":"13","author":"J Xia","year":"2014","unstructured":"Xia, J. et al. A meta-analysis of somatic mutations from next generation sequencing of 241 melanomas: a road map for the study of genes with potential clinical relevance. Mol. Cancer Ther. 13, 1918\u20131928 (2014).","journal-title":"Mol. Cancer Ther."},{"key":"826_CR29","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2023.1170026","volume":"10","author":"M Wozniak","year":"2023","unstructured":"Wozniak, M. & Czyz, M. lncRNAs-EZH2 interaction as promising therapeutic target in cutaneous melanoma. Front. Mol. Biosci. 10, 1170026 (2023).","journal-title":"Front. Mol. Biosci."},{"key":"826_CR30","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.ccell.2018.06.001","volume":"34","author":"D Zingg","year":"2018","unstructured":"Zingg, D. et al. EZH2-mediated primary cilium deconstruction drives metastatic melanoma formation. Cancer Cell 34, 69\u201384.e14 (2018).","journal-title":"Cancer Cell"},{"key":"826_CR31","doi-asserted-by":"publisher","first-page":"e2245269","DOI":"10.1001\/jamanetworkopen.2022.45269","volume":"5","author":"N Kahlon","year":"2022","unstructured":"Kahlon, N. et al. Melanoma treatments and mortality rate trends in the US, 1975 to 2019. JAMA Netw. Open 5, e2245269 (2022).","journal-title":"JAMA Netw. Open"},{"key":"826_CR32","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3322\/caac.21820","volume":"74","author":"RL Siegel","year":"2024","unstructured":"Siegel, R. L., Giaquinto, A. N. & Jemal, A. Cancer statistics, 2024. CA Cancer J. Clin. 74, 12\u201349 (2024).","journal-title":"CA Cancer J. Clin."},{"key":"826_CR33","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1001\/jamadermatol.2019.3353","volume":"156","author":"KG Paulson","year":"2020","unstructured":"Paulson, K. G. et al. Age-specific incidence of melanoma in the United States. JAMA Dermatol 156, 57\u201364 (2020).","journal-title":"JAMA Dermatol"},{"key":"826_CR34","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1056\/NEJMoa1203421","volume":"367","author":"KT Flaherty","year":"2012","unstructured":"Flaherty, K. T. et al. Improved survival with MEK inhibition in BRAF-mutated melanoma. N. Engl. J. Med. 367, 107\u2013114 (2012).","journal-title":"N. Engl. J. Med."},{"key":"826_CR35","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1016\/S0140-6736(12)60868-X","volume":"380","author":"A Hauschild","year":"2012","unstructured":"Hauschild, A. et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet 380, 358\u2013365 (2012).","journal-title":"Lancet"},{"key":"826_CR36","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa1003466","volume":"363","author":"FS Hodi","year":"2010","unstructured":"Hodi, F. S. et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363, 711\u2013723 (2010).","journal-title":"N. Engl. J. Med."},{"key":"826_CR37","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1056\/NEJMoa1910836","volume":"381","author":"J Larkin","year":"2019","unstructured":"Larkin, J. et al. Five-year survival with combined nivolumab and ipilimumab in advanced melanoma. N. Engl. J. Med. 381, 1535\u20131546 (2019).","journal-title":"N. Engl. J. Med."},{"key":"826_CR38","doi-asserted-by":"publisher","first-page":"3155","DOI":"10.1002\/cam4.3760","volume":"10","author":"MA Mangin","year":"2021","unstructured":"Mangin, M. A. et al. Decreased survival in patients treated by chemotherapy after targeted therapy compared to immunotherapy in metastatic melanoma. Cancer Med. 10, 3155\u20133164 (2021).","journal-title":"Cancer Med."}],"container-title":["npj Precision Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41698-025-00826-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41698-025-00826-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41698-025-00826-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T04:55:19Z","timestamp":1740113719000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41698-025-00826-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,21]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["826"],"URL":"https:\/\/doi.org\/10.1038\/s41698-025-00826-8","relation":{},"ISSN":["2397-768X"],"issn-type":[{"value":"2397-768X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,21]]},"assertion":[{"value":"23 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"C.A.P. has received research grants from Kura Oncology and Novartis Institutes for Biomedical Research (unrelated to this manuscript) and consulting fees from Day One Therapeutics (unrelated). Related to this manuscript, E.J.L. has received support from the Bloomberg~Kimmel Institute for Cancer Immunotherapy, the Marilyn and Michael Glosserman Fund for Basal Cell Carcinoma and Melanoma Research, the Barney Family Foundation, and the Laverna Hahn Charitable Trust. E.J.L is a consultant\/advisor for Agenus, Bristol-Myers Squibb, CareDx, Eisai, Genentech, HUYA Bioscience International, Immunocore, Instil Bio, Lyvgen, Merck, Merck KGaA, Natera, Nektar, Novartis, OncoSec, Pfizer, Rain Therapeutics, Regeneron, Replimune, Sanofi-Aventis, Sun Pharma, Syneos Health (unrelated). E.J.L. has institutional research funding from Bristol-Myers Squibb, Haystack Oncology, Merck, Regeneron, Sanofi (unrelated). EJ.L holds stock in Iovance Biotherapeutics (unrelated). The other co-authors declare that they have no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"48"}}